# FORE Biotherapeutics Closes $67.4M Series D-2 Extension to Advance BRAF Cancer Drug

> financing · REPORTED · 2026-07-07

Philadelphia-based FORE Biotherapeutics closed a $67.4 million extension of its Series D-2 round on July 7, 2026, bringing the total Series D-2 to $110 million, to fund late-stage testing of plixorafenib, a BRAF inhibitor being evaluated in the Phase 2 FORTE study for BRAF-mutated cancers including primary brain tumors. New investors include TaiAx, LG Technology Ventures, and Axil, alongside existing backers.

About FORE Biotherapeutics: FORE Biotherapeutics is a Philadelphia-based oncology biotech developing plixorafenib, an oral BRAF inhibitor designed to treat BRAF-driven solid tumors and primary central nervous system cancers.

- Company: FORE Biotherapeutics
- Sector: oncology
- Primary source: https://wewillcure.com/insights/news/funding-and-models/biotech-venture-funding-tracker

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.